What is the difference between a deviation, an OOS and an OOT result?
By Savi C., Co-Founder · Published Nov 16, 2026
The three terms side by side
Term
Deviation
What it is and where it comes from
A departure from an approved instruction or established standard (ICH Q7). In US GMP, 21 CFR 211.100(b) requires any deviation from written production procedures to be recorded and justified
Term
OOS result
What it is and where it comes from
A test result outside the specification or acceptance criteria set in an application, drug master file, compendium or by the manufacturer. FDA regulations require an investigation whenever one is obtained, under 211.192
Term
OOT result
What it is and where it comes from
A result within specification that departs from the pattern of previous results, for example a stability time point or an in-process value moving away from its usual range. Defined by your own procedures rather than by regulation
Deviations
A deviation is about the process, not a test result: a step done out of order, a hold time exceeded, a parameter outside its range, the wrong revision of a form used. Many quality systems also distinguish planned deviations, approved before the event, from unplanned ones discovered after it.
A deviation may or may not affect the product. If it leads to an unexplained discrepancy or a failure to meet specifications, it falls under the investigation requirement in 211.192. In the EU, Annex 16 section 3 lets a Qualified Person consider certifying a batch after an unexpected deviation only where registered specifications are met, the deviation has been thoroughly investigated and its impact assessed as negligible.
OOS results: how FDA expects them investigated
The FDA guidance describes two phases. Phase I is a laboratory investigation that assesses the accuracy of the data, ideally before test preparations are discarded. A result is invalidated only where there is clear evidence of laboratory error. If no clear lab error is found, Phase II is a full-scale investigation led by the quality unit, which reviews production and sampling, often includes additional laboratory testing, and evaluates the impact on batches already distributed.
Retesting must follow a predefined plan, often by a second analyst at least as experienced as the first, with the maximum number of retests set in advance in an SOP. Repeated testing until a passing result appears is what FDA calls testing into compliance, which it describes as unscientific and objectionable. Averaging can hide variability, and where individual results in a reportable series are OOS, FDA advises treating the average as OOS even when it falls within specification.
A confirmed OOS result means the batch does not meet its specification and should be rejected under 211.165(f), and the investigation becomes a batch failure investigation that extends to other batches and products. An inconclusive result must be given full consideration in the disposition decision. For distributed application products, a field alert report is due within 3 working days unless the result is found invalid in that time.
OOT results
An OOT result passes, which is why it is easy to ignore. The OOS guidance makes a related point about borderline results: a low assay that is still within specification should raise concern, because the batch may not have been formulated properly. Laboratory management is also expected to watch for developing trends.
In the EU, Annex 16 point 1.7.16 names out of trend investigations alongside out of specification investigations among those that must be complete enough to support certification. Because no US regulation defines OOT, your procedure has to: which data sets are trended, how the expected range is calculated, and what happens when a result falls outside it.
Classifying an event
Questions to ask first
- Is this a test result, or something that happened in the process or the record?
- If it is a result, is it outside the specification or acceptance criterion? Then it is OOS
- If it is within specification, is it outside the range your trending procedure defines? Then it is OOT
- If it is a departure from an instruction or standard, it is a deviation, whatever the test results show
Linking events
- An OOS traced to a process cause should be linked to the deviation that caused it
- Repeated OOT results in one direction may justify a deviation or CAPA before any result goes OOS
- Every linked record is referenced in the batch record before review is complete
How Litewave fits
Litewave reads paper or electronic records, checks every entry against your master record and specifications, and shows QA only the exceptions, each linked to the page it came from. That includes values outside their limits and deviations that are referenced but still open. Classification, investigation and disposition stay with your quality unit: Litewave proposes, qualified people approve.
Questions we get asked
Can a result be both OOS and a deviation?
Yes, and often it is. The OOS is the test result; if the investigation finds a process cause, the departure that caused it is a deviation. They are usually recorded separately and cross-referenced.
Is investigating OOT results required?
No US regulation defines OOT or requires a specific OOT procedure. FDA’s OOS guidance notes that much of it may be useful for out-of-trend results, and in the EU Annex 16 expects out of trend investigations for a batch to be sufficiently complete before a QP certifies it.
Can we report the average if the average passes?
Not to override individual OOS results. Where a reportable result is built from several sample preparations and some individual results are OOS, FDA advises treating the average as OOS even if it is within specification.
Sources
- FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (2022)
- ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
- 21 CFR 211.100, Written procedures; deviations (eCFR)
- 21 CFR 211.165, Testing and release for distribution (eCFR)
- 21 CFR 211.192, Production record review (eCFR)
- 21 CFR 314.81, Other postmarketing reports (eCFR)
- EudraLex Volume 4, Annex 16, Certification by a Qualified Person and Batch Release
